Drug Profile
Pseudo-ginsenoside GQ
Alternative Names: PGQLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Jilin Huakang Pharmaceutical
- Developer Jilin Huakang Pharmaceutical; Jilin University
- Class Cardiovascular therapies; Ginsenosides; Ischaemic heart disorder therapies; Saponins
- Mechanism of Action Calcium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Angina pectoris; Myocardial ischaemia
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Angina-pectoris in China
- 16 Jul 2016 No recent reports of development identified for phase-I development in Myocardial-ischaemia in China